MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition - Test2 - elhamkhani - TriplyDB

MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition

MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition

http://www.wikidata.org/entity/Q28270311

about

MicroRNAs in the DNA Damage/Repair Network and Cancer Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis The genetics of hair cell development and regeneration MicroRNAs, DNA Damage Response, and Cancer Treatment Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine The microRNA-183 cluster: the family that plays together stays together Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors p53 is positively regulated by miR-542-3p.MicroRNAs, genomic instability and cancer.Biphasic regulation of autophagy by miR-96 in prostate cancer cells under hypoxia.Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1 REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells Alteration of Aging-Dependent MicroRNAs in Idiopathic Pulmonary Fibrosis.Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer.High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.Non-coding RNAs in DNA damage and repair.Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair.HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material.The roles of DNA polymerase ζ and the Y family DNA polymerases in promoting or preventing genome instability.MicroRNAs and DNA damage response: implications for cancer therapy.Charity begins at home: non-coding RNA functions in DNA repair Resistance to PARP-Inhibitors in Cancer Therapy.microRNAs in cancer cell response to ionizing radiation.Targeting homologous recombination-mediated DNA repair in cancer.Targeting the microRNA-regulating DNA damage/repair pathways in cancer.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.MicroRNAs and Cancer Drug Resistance.Noncoding RNAs in Therapeutic Resistance of Cancer.The emerging role of lysine demethylases in DNA damage response: dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sites miR-96/HBP1/Wnt/β-catenin regulatory circuitry promotes glioma growth.miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells.Maintenance of Genome Integrity: How Mammalian Cells Orchestrate Genome Duplication by Coordinating Replicative and Specialized DNA Polymerases.Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer.

P2860

Q21284509-7805FFDF-A818-4684-AFCA-7DAC08C4AF5C Q26747871-0A51860E-96B5-4907-B17D-BC229469171F Q26864510-01113E23-49A8-43D0-B6B4-FC06E055DCE8 Q28067062-ADE9CFD9-A204-4C12-B451-8DDDE602BE28 Q28072204-BC027D7B-C85E-4580-9339-B67B6CB08B15 Q28080473-EA01CDFC-703A-48AD-8496-970269614394 Q28235715-06FBE8AF-ACB6-4115-9934-5BDF38964088 Q28240422-25EBAFFE-7C02-4B93-A271-8B625FEA7C77 Q28299698-69241F0A-D52D-4C39-B320-B603D140253F Q28829013-AB295263-1C81-4DC8-ACA4-71EB7396D919 Q33618910-1BCF397B-D2B1-46B9-9D53-9F6BA1F8BC0A Q33758261-3680C569-E3CF-4A53-9C4F-3F538AA88775 Q34158633-3E542526-6AE7-4DF6-A7BE-5EA65179C988 Q34619280-BEAC7AB1-B339-46C3-89BF-3CAA11C68055 Q34951635-A723D10B-384B-44F5-8FB1-7817FE2B584E Q35190445-F7249AE2-DFC8-4A81-BA91-9B09096C089E Q36189350-335ECD09-767F-4D62-B5E5-887BA70ABD58 Q36190899-0D86FFA3-92DC-4624-9268-38EF154F6FB4 Q36292777-866FC6B6-8C6A-4033-A025-BCD75FB3505C Q36780751-A78DB71F-BADF-46F3-B0EB-18CCFF45F10A Q37009459-1A158BE6-962E-4537-B3D3-55534D06D9A3 Q37046504-18BD25CC-50A4-4DAA-A5E9-191C4CAB1D9D Q37100102-23F960B3-D9CF-4D81-A11F-317D73064CC4 Q37279318-9411818A-9BD1-4C67-8A53-44F1B4541E68 Q38063711-B555B801-BFE7-425E-AC67-018C15A236A2 Q38068797-EBC57FDA-69B4-43C8-8808-1ABF38D0736D Q38079476-D5F98FC6-D32B-41A0-B44A-8DE695F1F221 Q38085600-0CC3A04D-A263-4F2C-BF34-1B2CE2A06CEC Q38160950-9E2BD3B4-69C9-496F-8E01-A55C6A0F9EE2 Q38184667-9EF12D1B-910B-4A08-B9CB-B8AA1E5232F0 Q38246220-5A584D82-FBA0-4B8F-BB3C-3393B4A65ED7 Q38633144-D8DADAA1-D62A-4335-A0B0-0DFC01F958E9 Q38748118-20026861-D167-4FD7-9AE3-EF7DB05B3987 Q38885495-9D56CC56-59AC-482C-8B52-81456593787E Q38906175-181CECDD-941E-4136-ABE8-AB0722C05E02 Q38984513-C15B0F04-594A-4EEA-A296-340197078FCC Q39014980-735B972C-CCE5-4A97-866B-F9673AD5F4D1 Q39031967-BE8F0893-D4D4-484F-AADD-6386D420CF68 Q40221884-3F2E7E0D-5AB8-4CAC-9078-CFB43CA78C62 Q41024459-69B11DD7-C0AB-401C-95CC-DB6204A505F0

P2860

MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition

http://www.wikidata.org/entity/Q28270311

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@ast

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@en

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@nl

type

label

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@ast

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@en

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@nl

prefLabel

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@ast

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@en

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@nl

P1433

Q28270311-8BA32C7F-74AA-489D-A3BF-8EC9E8F28B1D

P1476

Q28270311-E378B0DA-E682-498D-AE13-58AA9C4370E8

P2093

Q28270311-03D6F7A2-0237-4342-89A3-F8C930AD9E8B

Q28270311-04C74D44-9E5C-451F-B30E-F5FDF8A30E80

Q28270311-21F1110B-55B0-4129-8290-137EC5535AC9

Q28270311-59545979-BB70-4AAD-A626-F1BC938550B7

P2860

Q28270311-0345B835-B4C7-4898-B535-89264248CFE4

Q28270311-04E1F27C-0F6F-4FF0-B9B2-FF737FA80F10

Q28270311-04F9AEEB-1DD8-4F2C-822C-92EDE20E6700

Q28270311-11BE7627-0B60-4808-9D20-A22AFD735F86

Q28270311-1982A15A-6FB5-422F-B8EC-987ACC6DDEB4

Q28270311-1A5E51DF-6E27-451B-B98E-E75A57561CAC

Q28270311-1F10BD09-6457-452B-ADD7-0E56A78FA951

Q28270311-206BECF1-E35F-416F-9836-B830260D1F89

Q28270311-22C4650F-6984-44D6-95B4-036983CF5E4E

Q28270311-261F8254-3D64-41B4-8DCD-B868E40BCC96

P304

Q28270311-30312C7B-BDB7-406C-8CF3-0F8ECB8EDA0C

P31

Q28270311-5C39E530-FA4E-402D-8F79-690DF4CFA08A

P3181

Q28270311-AA3C8F77-18C2-4F9C-931D-C4136B08597E

P356

Q28270311-580D4C32-291D-407D-BF14-DC60B653C399

P407

Q28270311-8F52CE46-B5C7-4F4D-8055-16D8FD34C988

P433

Q28270311-C77D1994-B395-4069-8706-279F01B36A95

P478

Q28270311-6DF17763-51BB-46AC-915E-857CF215A114

P50

Q28270311-69D67839-6418-4E3A-9ECF-B54FBF8FCCC8

P577

Q28270311-6EA8EAA5-FBCA-4A20-B317-9271F683084D

P5875

Q28270311-964E4600-BDAF-49AF-ADF4-B5F9F916EB50

P698

Q28270311-8ED05D92-25F5-404D-BC28-401799619E76

P932

Q28270311-868D75B6-2CAB-467C-90D6-348B109F3486

P3181

P356

0008-5472.CAN-12-0103

P1433

Cancer Research

P1476

MiR-96 downregulates REV1 and ...... cisplatin and PARP inhibition

@en

P2093

Christopher J Kemp

http://www.w3.org/2001/XMLSchema#string

Jen-Wei Huang

http://www.w3.org/2001/XMLSchema#string

Philamer Calses

http://www.w3.org/2001/XMLSchema#string

Yemin Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states

MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression

Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes

DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells

miR-221 overexpression contributes to liver tumorigenesis

Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

The DNA Damage Response: Making It Safe to Play with Knives

Genetic analysis of BRCA1 function in a defined tumor cell line

Unraveling the mechanism of BRCA2 in homologous recombination

P304

4037-4046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3901796

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-12-0103

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Toshiyasu Taniguchi

P577

2012-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228116084

http://www.w3.org/2001/XMLSchema#string

P698

22761336

http://www.w3.org/2001/XMLSchema#string

P932

3421071

http://www.w3.org/2001/XMLSchema#string